DSpace university logo mark
詳細検索
Japanese | English 

NAOSITE : Nagasaki University's Academic Output SITE > 130 病院 > 130 学術雑誌論文 >

Hepatitis C virus kinetics during the first phase of pegylated interferon-alpha-2b with ribavirin therapy in patients with living donor liver transplantation.


ファイル 記述 サイズフォーマット
HepRes39_856.pdf182.66 kBAdobe PDF本文ファイル

タイトル: Hepatitis C virus kinetics during the first phase of pegylated interferon-alpha-2b with ribavirin therapy in patients with living donor liver transplantation.
著者: Ichikawa, Tatsuki / Nakao, Kazuhiko / Miyaaki, Hisamitsu / Eguchi, Susumu / Takatsuki, Mitsuhisa / Fujimito, Masumi / Akiyama, Motohisa / Miuma, Satoshi / Ozawa, Eisuke / Shibata, Hidetaka / Takeshita, Shigeyuki / Kanematsu, Takashi / Eguchi, Katsumi
発行日: 2009年 9月
出版者: Blackwell Publishing Inc.
引用: Hepatology research, 39(9), pp.856-864; 2009
抄録: Aim: To identify the problems of pegylated interferon (PEG IFN) with ribavirin therapy against hepatitis C virus (HCV) reinfection in living donor liver transplantation (LDLT) patients. HCV kinetics during the PEG IFN with ribavirin therapy were analyzed in LDLT patients, as well as in chronic hepatitis C (CHC) patients. Methods: The study included 80 consecutive HCV infected patients undergoing PEG IFN with ribavirin therapy (64 CHC and 16 LDLT patients) who attended the Nagasaki University Hospital for an initial visit between January 2005 and December 2007. Results: The sustained viral response (VR) rate of the CHC group (80%) was superior to the LDLT group (22%). The viral disappearance rate of the CHC group was also superior to the LDLT group, regardless of the HCV serotype. The HCV core antigen (cAg) titer under treatment in the LDLT group was more than that of the CHC group from day 0 to week 12. The HCV cAg decrease rate of the LDLT group on the first day of treatment was less than that of the CHC group. Conclusion: The HCV infection of a transplanted liver is more refractory to treatment than a non-transplanted liver. The low reduction HCV cAg rate on day 1 is one of the problems of the combination therapy.
キーワード: Chronic hepatitis C / First phase / Hepatitis C virus / Interferon / Living donor liver transplantation
URI: http://hdl.handle.net/10069/24038
ISSN: 13866346
DOI: 10.1111/j.1872-034X.2009.00524.x
PubMed ID: 19624776
権利: © 2009 The Japan Society of Hepatology / This is the author's version of the work. It is posted here by permission of The Japan Society of Hepatology for personal use, not for redistribution. The definitive version was published in Hepatology Research, Volume 39, Issue 9, Pages 856-864. http://dx.doi.org/10.1111/j.1872-034X.2009.00524.x
資料タイプ: Journal Article
原稿種類: author
出現コレクション:130 学術雑誌論文

引用URI : http://hdl.handle.net/10069/24038

このリポジトリに保管されている文献はすべて著作権により保護されています。
印刷やダウンロード等データの複製は、調査研究・教育または学習を目的とする場合に限定されます。

 

Valid XHTML 1.0! Copyright © 2006-2015 長崎大学附属図書館 - お問い合わせ Powerd by DSpace